Back

SARS-CoV-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan

Morokutti-Kurz, M.; Graf, P.; Grassauer, A.; Prieschl-Grassauer, E.

2020-07-28 cell biology
10.1101/2020.07.28.224733 bioRxiv
Show abstract

In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mediated by the spike glycoprotein (SGP). Recently, a SARS-CoV-2 Spike Pseudotyped Lentivirus (SSPL) was developed that allows studying spike-mediated cell entry via luciferase reporter activity in a BSL2 environment. Here, we show that iota-carrageenan can inhibit the cell entry of SSPL in a dose dependent manner. SSPL particles were efficiently neutralized with an IC50 value of 2.6 {micro}g/ml iota-carrageenan. In vitro data on iota-carrageenan against various Rhino- and Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SSPL suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.